Visiting from the United States? GLPInfo has a North American edition with US channels and dollar prices: open the US edition. Canada follows in a later release.
Research → decisions → accessEvidence checked 13 Sep 2026
Follow the science. See what comes next.
A clearer view of the milestones shaping peptide and GLP-1 medicines in the UK, US and EU: confirmed decisions, company targets and clearly labelled estimates, each with its source. What we track · How estimates are made.
Tirzepatide
Eli Lilly · GIP and GLP-1 receptor agonist · Peptide
Confirmed eventCompany targetRegulator targetEditorial estimateTiming unknown or undatedSafety update
Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Confirmed · 20 Dec 2024United States
FDA approves Zepbound for moderate to severe obstructive sleep apnoea in adults with obesity
Supplement 13 to NDA 217806 approved on 20 December 2024: the first medicine approved to treat obstructive sleep apnoea, for adults with obesity, alongside diet and physical activity.
Why it matters. The workbook gave one date for both Zepbound indications; the sleep-apnoea indication is a separate event thirteen months later.
Event
Approval
Indication
Obstructive sleep apnoea (Moderate to severe OSA with obesity)
Once-weekly dual GIP and GLP-1 receptor agonist marketed for type 2 diabetes and weight management; Zepbound in the US also carries an obstructive sleep apnoea indication.
United Kingdom
No verified events recorded yet. Regulator: MHRA.
United States
· Approval Confirmed
FDA approves Mounjaro (tirzepatide) for type 2 diabetes
Mounjaro (once-weekly injection) · Type 2 diabetes (glycaemic control)
Original approval of NDA 215866 on 13 May 2022 to improve glycaemic control in adults with type 2 diabetes.
Why it matters: The first dual GIP and GLP-1 receptor agonist. Its weight-management use in the US is a separate product (Zepbound).
Original approval of NDA 217806 on 8 November 2023 for chronic weight management in adults with obesity, or overweight with a weight-related condition.
Why it matters: Same molecule as Mounjaro, separate US brand and application for the weight-management indication. In the UK and EU tirzepatide is marketed as Mounjaro for both uses.
Supplement 13 to NDA 217806 approved on 20 December 2024: the first medicine approved to treat obstructive sleep apnoea, for adults with obesity, alongside diet and physical activity.
Why it matters: The workbook gave one date for both Zepbound indications; the sleep-apnoea indication is a separate event thirteen months later.
No verified events recorded yet. Regulator: EMA / European Commission.
This list is the complete, accessible view of the tracker; the board above draws from exactly the same records. Every entry is labelled Confirmed (official record), Company target (a dated sponsor statement), Regulator target (an official decision date, not a guarantee), GLPInfo estimate (an editorial range with assumptions) or Timing unknown. An approval is never inferred from a target date passing.